{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:29:59Z","timestamp":1740173399113,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:00:00Z","timestamp":1595721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T00:00:00Z","timestamp":1595721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"crossref","award":["LP120200623"],"award-info":[{"award-number":["LP120200623"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG"},{"name":"Queensland Government Smart State Research Facilities Programme"},{"DOI":"10.13039\/501100020111","name":"Therapeutic Innovation Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100020111","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s43440-020-00145-8","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T14:11:06Z","timestamp":1596118266000},"page":"1418-1425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of the anti-allodynic efficacy of a glycine transporter 2 inhibitor relative to pregabalin and duloxetine in a rat model of prostate cancer-induced bone pain"],"prefix":"10.1007","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6919-9781","authenticated-orcid":false,"given":"Mohammad Zafar","family":"Imam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6395-3114","authenticated-orcid":false,"given":"Andy","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet R.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2281-3734","authenticated-orcid":false,"given":"Maree T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,26]]},"reference":[{"key":"145_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10787-013-0183-7","volume":"21","author":"A Muralidharan","year":"2013","unstructured":"Muralidharan A, Smith MT. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology. 2013;21:339\u201363.","journal-title":"Inflammopharmacology"},{"key":"145_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2058738419838383","volume":"33","author":"E Cavalli","year":"2019","unstructured":"Cavalli E, Mammana S, Nicoletti F, Bramanti P, Mazzon E. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019;33:1\u201310.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"145_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.brainresbull.2019.07.008","volume":"152","author":"M Al-Khrasani","year":"2019","unstructured":"Al-Khrasani M, Mohammadzadeh A, Balogh M, Kiraly K, Barsi S, Hajnal B, et al. Glycine transporter inhibitors: A new avenue for managing neuropathic pain. Brain Res Bull. 2019;152:143\u201358.","journal-title":"Brain Res Bull"},{"key":"145_CR4","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1111\/bph.14189","volume":"175","author":"BL Winters","year":"2018","unstructured":"Winters BL, Rawling T, Vandenberg RJ, Christie MJ, Bhola RF, Imlach WL. Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord. Br J Pharmacol. 2018;175:2337\u201347.","journal-title":"Br J Pharmacol"},{"key":"145_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.tips.2014.05.006","volume":"35","author":"RJ Vandenberg","year":"2014","unstructured":"Vandenberg RJ, Ryan RM, Carland JE, Imlach WL, Christie MJ. Glycine transport inhibitors for the treatment of pain. Trends Pharmacol Sci. 2014;35:423\u201330.","journal-title":"Trends Pharmacol Sci"},{"key":"145_CR6","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1213\/ANE.0000000000000388","volume":"119","author":"N Motoyama","year":"2014","unstructured":"Motoyama N, Morita K, Shiraishi S, Kitayama T, Kanematsu T, Uezono Y, et al. Relief of cancer pain by glycine transporter inhibitors. Anesth Analg. 2014;119:988\u201395.","journal-title":"Anesth Analg"},{"key":"145_CR7","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1021\/acs.jmedchem.8b01775","volume":"62","author":"SN Mostyn","year":"2019","unstructured":"Mostyn SN, Rawling T, Mohammadi S, Shimmon S, Frangos ZJ, Sarker S, et al. Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain. J Med Chem. 2019;62:2466\u201384.","journal-title":"J Med Chem"},{"key":"145_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pbb.2013.02.020","volume":"106","author":"A Muralidharan","year":"2013","unstructured":"Muralidharan A, Wyse BD, Smith MT. Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacol Biochem Behav. 2013;106:33\u201346.","journal-title":"Pharmacol Biochem Behav"},{"key":"145_CR9","unstructured":"Nagasue H, Nishida H, Saitoh F, Yumiya Y, Ohkouchi M, Egusa T, et al. 4-Phenoxy-benzamide derivatives as novel glycine transporter type 2 inhibitors. Part 2: 3-Pyridyl amide derivatives; a new class of potent and orally active GlyT-2 inhibitors (Abstract). In: AIMECS 11: The 8th AFMC international medicinal chemistry symposium, vol. 2P-134; 2011."},{"key":"145_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jphs.2015.02.010","volume":"127","author":"Y Omori","year":"2015","unstructured":"Omori Y, Nakajima M, Nishimura K, Takahashi E, Arai T, Akahira M, et al. Analgesic effect of GT-0198, a structurally novel glycine transporter 2 inhibitor, in a mouse model of neuropathic pain. J Pharmacol Sci. 2015;127:377\u201381.","journal-title":"J Pharmacol Sci"},{"key":"145_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1200\/JCO.18.00896","volume":"37","author":"J Jiang","year":"2018","unstructured":"Jiang J, Li Y, Shen Q, Rong X, Huang X, Li H, et al. Effect of pregabalin on radiotherapy-related neuropathic pain in patients with head and neck cancer: A randomized controlled trial. J Clin Oncol. 2018;37:135\u201343.","journal-title":"J Clin Oncol"},{"key":"145_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40780-016-0063-6","volume":"2","author":"R Yajima","year":"2016","unstructured":"Yajima R, Matsumoto K, Ise Y, Suzuki N, Yokoyama Y, Kizu J, et al. Pregabalin prescription for terminally ill cancer patients receiving specialist palliative care in an acute hospital. J Pharmaceut Health care Sci. 2016;2:29.","journal-title":"J Pharmaceut Health care Sci"},{"key":"145_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40122-013-0009-8","volume":"2","author":"K-F Sj\u00f6lund","year":"2013","unstructured":"Sj\u00f6lund K-F, Yang R, Lee K-H, Resnick M. Randomized study of pregabalin in patients with cancer-induced bone pain. Pain Therapy. 2013;2:37\u201348.","journal-title":"Pain Therapy"},{"key":"145_CR14","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","volume":"20","author":"Y Hirayama","year":"2015","unstructured":"Hirayama Y, Ishitani K, Sato Y, Iyama S, Takada K, Murase K, et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol. 2015;20:866\u201371.","journal-title":"Int J Clin Oncol"},{"key":"145_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jpainsymman.2019.06.020","volume":"58","author":"H Matsuoka","year":"2019","unstructured":"Matsuoka H, Iwase S, Miyaji T, Kawaguchi T, Ariyoshi K, Oyamada S, et al. Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08). J Pain Symptom Manage. 2019;58:645\u201353.","journal-title":"J Pain Symptom Manage"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00145-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-020-00145-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-020-00145-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,25]],"date-time":"2021-07-25T23:33:22Z","timestamp":1627256002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-020-00145-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,26]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1007\/s43440-020-00145-8","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2020,7,26]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"JN and LC are paid employees of Boehringer Ingelheim Pharma GmbH & Co. KG. The other three authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}